

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bengt Sandberg, et al.

U.S. Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: : June 15, 2001 (Herewith)

Examiner: To Be Assigned

For : BIOTIN DERIVATIVES

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to or concurrent with calculation of the filing fees, please amend this application as follows.

IN THE CLAIMS

Applicants have attached to this Preliminary Amendment documents entitled "Amended Claims" and "'Marked-up' Copy of the Previous Claims". Please replace present claims 10, 11 and 17 in this application with amended claims 10, 11 and 17 shown in the document entitled "Amended Claims".

REMARKS


Entry and consideration of this Preliminary Amendment courteously are solicited prior to or concurrent with calculation of the filing fees with respect to the claim set presented with the Preliminary Examination Report being filed herewith.

Atty. Docket No.:
33700WD004

Examination on the merits is awaited.

Respectfully submitted,

SMITH, GAMBRELL & RUSSELL, LLP

By: 
Michael K. Carrier, Reg. No. 42,391
1850 M Street, N.W., Suite 800
Washington, D.C. 20036
Telephone: (202) 659-2811
Fax: (202) 263-4329


June 15, 2001











“Marked-Up” Copy of the Previous Claims

"Marked-Up" Copy of Previous Claims


10. Method according to [any of the previous claims] claim 1, wherein the toxin binding moiety is biotin, the spacers a, b, and c are 4, 7, 10-trioxa-1, 13-tridecanediamine and the trifunctional cross-linking moiety is 5-amino-1, 3-dicarboxybenzene.

11. Method according to [any of the claims 1-9] claim 1, wherein it is





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100



17. Method according to [any of claims 13-16] claim 13, wherein the biotinylated targeting biomolecules are targeting molecules containing natural biotin or derivatives thereof, the biotin-binding molecules are molecules containing avidin, streptavidin or derivatives thereof, the biotinylated molecules are radiolabelled biotin derivatives containing a radiometal chelation moiety, and the effector molecule is a radionuclide or a cytotoxic agent.


PCT/EP2017/062006


Amended Claims


Amended Claims

10. Method according to claim 1, wherein the toxin binding moiety is biotin, the spacers a, b, and c are 4, 7, 10-trioxa-1, 13-tridecanediamine and the trifunctional cross-linking moiety is 5-amino-1, 3-dicarboxybenzene.

11. Method according to claim 1, wherein it is







10
9
8
7
6
5
4
3
2
1

17. Method according to claim 13, wherein the biotinylated targeting biomolecules are targeting molecules containing natural biotin or derivatives thereof,
the biotin-binding molecules are molecules containing avidin, streptavidin or derivatives thereof,
the biotinylated molecules are radiolabelled biotin derivatives containing a radiometal chelation moiety, and the effector molecule is a radionuclide or a cytotoxic agent.